DBV Now Plans BLA Submission For Viaskin Peanut Patch In Children 4 - 7-years-old In H1, 2026

(RTTNews) - DBV Technologies announced that in a Written Responses to the Type D IND meeting request, the FDA agreed with the company's proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4 - 7-year-olds will be sufficient to support https://www.nasdaq.com/articles/dbv-now-plans-bla-submission-viaskin-peanut-patch-children-4-7-years-old-h1-2026